TransCode Therapeutics, Inc.
RNAZ · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.01 | -0.01 | -16.54 |
| FCF Yield | -56.76% | -78.28% | -0.28% | -0.04% |
| EV / EBITDA | -1.10 | -1.16 | -323.12 | -2,262.58 |
| Quality | ||||
| ROIC | -340.51% | -928.50% | -575.98% | -30.15% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.80 | 0.97 | 0.90 | 0.77 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 26.24% | -14.16% | -187.29% | -1,020.09% |
| Safety | ||||
| Net Debt / EBITDA | 0.36 | 0.13 | 0.28 | 3.41 |
| Interest Coverage | -584.07 | -347.39 | -1.06 | -64.70 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.18 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | -13,216.50 | -17,328.96 |